316 related articles for article (PubMed ID: 9496257)
21. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
22. Localization of thrombospondin and its cysteine-serine-valine-threonine-cysteine-glycine-specific receptor in human breast carcinoma.
Tuszynski GP; Nicosia RF
Lab Invest; 1994 Feb; 70(2):228-33. PubMed ID: 7511188
[TBL] [Abstract][Full Text] [Related]
23. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
24. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Half E; Tang XM; Gwyn K; Sahin A; Wathen K; Sinicrope FA
Cancer Res; 2002 Mar; 62(6):1676-81. PubMed ID: 11912139
[TBL] [Abstract][Full Text] [Related]
25. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer.
Papa V; Gliozzo B; Clark GM; McGuire WL; Moore D; Fujita-Yamaguchi Y; Vigneri R; Goldfine ID; Pezzino V
Cancer Res; 1993 Aug; 53(16):3736-40. PubMed ID: 8339284
[TBL] [Abstract][Full Text] [Related]
26. Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast.
Vos CB; Ter Haar NT; Peterse JL; Cornelisse CJ; van de Vijver MJ
J Pathol; 1999 Feb; 187(3):279-84. PubMed ID: 10398079
[TBL] [Abstract][Full Text] [Related]
27. Significant expression of IGFBP2 in breast cancer compared with benign lesions.
Busund LT; Richardsen E; Busund R; Ukkonen T; Bjørnsen T; Busch C; Stalsberg H
J Clin Pathol; 2005 Apr; 58(4):361-6. PubMed ID: 15790698
[TBL] [Abstract][Full Text] [Related]
28. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
[TBL] [Abstract][Full Text] [Related]
29. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
[TBL] [Abstract][Full Text] [Related]
30. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
31. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia.
Gillett CE; Lee AH; Millis RR; Barnes DM
J Pathol; 1998 Apr; 184(4):396-400. PubMed ID: 9664905
[TBL] [Abstract][Full Text] [Related]
32. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast.
Kominsky SL; Argani P; Korz D; Evron E; Raman V; Garrett E; Rein A; Sauter G; Kallioniemi OP; Sukumar S
Oncogene; 2003 Apr; 22(13):2021-33. PubMed ID: 12673207
[TBL] [Abstract][Full Text] [Related]
33. Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma.
Bhardwaj B; Klassen J; Cossette N; Sterns E; Tuck A; Deeley R; Sengupta S; Elliott B
Clin Cancer Res; 1996 Apr; 2(4):773-82. PubMed ID: 9816230
[TBL] [Abstract][Full Text] [Related]
34. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer.
Tong AW; Papayoti MH; Netto G; Armstrong DT; Ordonez G; Lawson JM; Stone MJ
Clin Cancer Res; 2001 Mar; 7(3):691-703. PubMed ID: 11297266
[TBL] [Abstract][Full Text] [Related]
35. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical assay for oestrogen receptors in paraffin wax sections of breast carcinoma using a new monoclonal antibody.
Huang A; Pettigrew NM; Watson PH
J Pathol; 1996 Oct; 180(2):223-7. PubMed ID: 8976884
[TBL] [Abstract][Full Text] [Related]
37. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications.
Acs G; Lawton TJ; Rebbeck TR; LiVolsi VA; Zhang PJ
Am J Clin Pathol; 2001 Jan; 115(1):85-98. PubMed ID: 11190811
[TBL] [Abstract][Full Text] [Related]
38. Epithelial (E-) and placental (P-) cadherin cell adhesion molecule expression in breast carcinoma.
Rasbridge SA; Gillett CE; Sampson SA; Walsh FS; Millis RR
J Pathol; 1993 Feb; 169(2):245-50. PubMed ID: 8383197
[TBL] [Abstract][Full Text] [Related]
39. Differential expression of keratins 13 and 16 in normal epithelium, benign lesions, and ductal carcinomas of the human breast determined by the monoclonal antibody Ks8.12.
Pellegrino MB; Asch BB; Connolly JL; Asch HL
Cancer Res; 1988 Oct; 48(20):5831-6. PubMed ID: 2458830
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical demonstration of growth factors, TGF-alpha, TGF-beta, IGF-I and neu oncogene product in benign and malignant human breast tissues.
Mizukami Y; Nonomura A; Yamada T; Kurumaya H; Hayashi M; Koyasaki N; Taniya T; Noguchi M; Nakamura S; Matsubara F
Anticancer Res; 1990; 10(5A):1115-26. PubMed ID: 1978632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
